Article from PolySciTech regarding polymer analysis
PolySciTech (www.polyscitech.com) provides a wide array of biodegradable
polymers and related block copolymers. In addition to this, contract analysis
is also offered for a variety of polymer-based and other samples. Recently our
group has published a paper detailing methodology of polymer analysis
post-formulation in parental products. Read more: Garner, John, Sarah Skidmore, Haesun
Park, Kinam Park, Stephanie Choi, and Yan Wang. "A Protocol for Assay of
Poly (lactide-co-glycolide) in Clinical Products." International Journal of Pharmaceutics (2015). http://www.sciencedirect.com/science/article/pii/S0378517315301605
“Abstract:
Poly(lactide-co-glycolide) (PLGA) is the key component of long acting drug
products responsible for providing sustained release in a controlled manner.
The objective of the current study was to develop and validate an analytical protocol
to determine key properties of PLGA used in commercial long-acting drug
products. Procedures to isolate PLGA from commercial products have been
established and the key properties of PLGA, such as polymer molecular weight,
lactide:glycolide (L:G) ratio, and nature of polymer end-cap, have been
determined. Identification of the polymer end-cap was confirmed by using two
PLGA polymers with acid and ester end-caps. Trelstar® and Risperdal Consta®
were chosen as model products. The calculated L:G ratios of PLGA used in
Trelstar® and Risperdal® are 52:48 and 78:22, respectively. PLGAs from both
Trelstar® and Risperdal Consta® possess ester end-caps. Since the properties of
specific PLGA in clinically used formulations are not readily available, this
protocol will be useful in developing PLGA-based long acting drug products.”
No comments:
Post a Comment